Subcortical targets involved in the action of psilocybin in learned and innate escape behaviors
Project Number5F30DA059437-02
Former Number1F30MH131298-01A1
Contact PI/Project LeaderDAVOUDIAN, PASHA A
Awardee OrganizationYALE UNIVERSITY
Description
Abstract Text
PROJECT TITLE
Subcortical targets involved in the action of psilocybin in learned and innate escape behaviors
PROJECT SUMMARY
Mood disorders such as depression now represent a leading cause of disability throughout the world,
with conventional first-line treatments failing to provide relief for most patients. In recent years, novel
treatments with fast-acting properties have garnered significant interest as innovative therapies. The
psychedelic psilocybin, in particular has recently gained attention for its ability to produce substantial and rapid
antidepressant effects in early-phase clinical trials. This combination of increasing need and exciting
preliminary clinical results has led to the recent ‘breakthrough therapy’ status designation for psilocybin to be
studied as a treatment for major depressive disorder. Yet despite these exciting results in pilot clinical trials, the
neurobiology underlying the effect of psilocybin remains less understood. Thus, a critical opportunity to further
our understanding of the action of psilocybin will be addressed here.
Among early studies examining the mechanisms of action of psilocybin, most have focused on the
neocortex and hippocampus. However, previous cellular and circuit-level research has clearly implicated
subcortical structures as key in the action of psilocybin. Our own preliminary work using whole-brain cFos
mapping has identified several candidate subcortical regions that are modulated by psilocybin. Aim 1 will
determine the activity of two of these key subcortical brain regions via in vivo recording with high-density silicon
probes to determine how neural activity changes following systemic psilocybin administration. Aim 2 will use
causal manipulation during psilocybin treatment to determine the relative role of subcortical regions during
innate and learned escape behaviors in mice. Specifically, chemogenetics will be used to bidirectionally control
brain region activity during a looming stimulus and learned escape behavioral paradigms. Cumulatively, this
work will determine the relative roles of key subcortical brain regions in the action of psilocybin during escape
behaviors and expand the framework for psilocybin’s use in clinical treatment.
Public Health Relevance Statement
PROJECT TITLE
Subcortical targets involved in the action of psilocybin in learned and innate escape behaviors
Project Narrative
Psilocybin represents a potentially revolutionary treatment for depression, a leading cause of disability.
However, while preliminary clinical trials are encouraging, knowledge of the mechanisms underlying this effect
are less understood and focus predominately on the cortex and hippocampus. This proposal will examine the
roles of subcortical brain regions in the action of psilocybin during learned and innate escape behaviors,
broadening the approach and understanding for the treatment of depression.
No Sub Projects information available for 5F30DA059437-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F30DA059437-02
Patents
No Patents information available for 5F30DA059437-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F30DA059437-02
Clinical Studies
No Clinical Studies information available for 5F30DA059437-02
News and More
Related News Releases
No news release information available for 5F30DA059437-02
History
No Historical information available for 5F30DA059437-02
Similar Projects
No Similar Projects information available for 5F30DA059437-02